CC
VERV

Casdin Capital’s Verve Therapeutics VERV Stock Holding History

Casdin Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,095,571
Closed -$46M – 38
2025
Q2 		$46M Buy
4,095,571
+100,000
+3% +$570K 4.19% 7
2025
Q1 		$18.3M Hold
3,995,571
– – 1.49% 13
2024
Q4 		$22.5M Hold
3,995,571
– – 1.5% 16
2024
Q3 		$19.3M Buy
3,995,571
+936,477
+31% +$5.44M 1.29% 18
2024
Q2 		$14.9M Hold
3,059,094
– – 1.14% 20
2024
Q1 		$40.6M Buy
3,059,094
+50,000
+2% +$663K 3.02% 11
2023
Q4 		$41.9M Buy
3,009,094
+54,384
+2% +$674K 4.12% 8
2023
Q3 		$39.2M Buy
2,954,710
+594,139
+25% +$9.57M 4.34% 7
2023
Q2 		$44.3M Buy
2,360,571
+240,000
+11% +$4M 3.87% 9
2023
Q1 		$30.6M Sell
2,120,571
-170,000
-7% -$3.33M 2.52% 13
2022
Q4 		$44.3M Sell
2,290,571
-887,596
-28% -$23.5M 3.43% 10
2022
Q3 		$109M Buy
3,178,167
+40,000
+1% +$1.28M 7.17% 6
2022
Q2 		$48M Hold
3,138,167
– – 4.05% 10
2022
Q1 		$71.6M Hold
3,138,167
– – 3.21% 12
2021
Q4 		$116M Buy
3,138,167
+100,000
+3% +$4.2M 3.26% 14
2021
Q3 		$143M Hold
3,038,167
– – 3.55% 10
2021
Q2 		$183M Buy
+3,038,167
New +$126M 4.65% 5

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Casdin Capital's VERV Position: Q3 2025 in Review

Casdin Capital sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 4,095,571 shares — an estimated $46M sold.

Casdin Capital first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $183M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Casdin Capital reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Casdin Capital sold 4,095,571 Verve Therapeutics shares in Q3 2025, an estimated $46M.
  • Casdin Capital first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Casdin Capital's Verve Therapeutics position peaked at $183M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.